Literature DB >> 11255083

Differentiated thyroid carcinoma in the elderly.

K M van Tol1, E G de Vries, R P Dullaart, T P Links.   

Abstract

The overall prognosis of patients with differentiated thyroid cancer is excellent, but the prognosis is rapidly worsening, when the disease is diagnosed in elderly patients. Old patients more often present with poor prognostic features, such as large tumors, follicular or Hürthle cell subtypes, extrathyroidal growth and distant metastases. Therefore, an optimal therapeutic approach is recommended. Current therapy includes a total thyroidectomy, if necessary combined with a lymph node dissection and followed by high dose radioiodine ablation. Radioiodine therapy in elderly patients meets specific problems, concerning thyroid hormone withdrawal, side effects of 131I and nursing problems. Additional treatment of residual, recurrent or metastatic disease must be tailored, according to the stage of the disease, and should not be denied on the basis of chronological age. Lifelong treatment with suppressive thyroid hormone therapy does not lead to important long-term side effects at old age.

Entities:  

Mesh:

Year:  2001        PMID: 11255083     DOI: 10.1016/s1040-8428(00)00127-x

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  2 in total

1.  Clinicopathological features of thyroid cancer in the elderly compared to younger counterparts: single-center experience.

Authors:  F D Dellal; D Özdemir; A A Tam; H Baser; H Tatli Dogan; O Parlak; R Ersoy; B Cakir
Journal:  J Endocrinol Invest       Date:  2016-11-24       Impact factor: 4.256

2.  Differentiated thyroid carcinoma in the elderly: influence of age on disease-free and overall survival.

Authors:  Juan J Díez; Emma Anda; Victoria Alcazar; María L Isidro; Cristina Familiar; Miguel Paja; Patricia Rojas Marcos; Begoña Pérez-Corral; Elena Navarro; Ana R Romero-Lluch; Amelia Oleaga; María J Pamplona; José C Fernández-García; Ana Megía; Laura Manjón; Cecilia Sánchez-Ragnarsson; Pedro Iglesias; Julia Sastre
Journal:  Endocrine       Date:  2022-05-18       Impact factor: 3.925

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.